

# Symptom Control & Quality of Life Committee

## Leadership

Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD

## Time/Location

Friday, October 13, 2023 7:30 a.m. - 9:30 a.m.  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

### Presentations

Evaluation and Measurement of Cognitive Function in Patients with Cancer:  
 Lessons Learned from Cooperative Group Trials  
 Plenary speaker: Jeffrey Wefel, PhD, ABPP

SWOG PRO Core: The Essential Core that Supports PRO Development in  
 SWOG Treatment Trials  
 Speaker: Riha Vaidya, PhD

### Active Trials

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating  
 The Effect Of Immune-Enhancing Nutrition On Radical Cystectomy  
 Outcomes"- Dr. Hamilton-Reeves.

**S2013**, "Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective  
 Observational Study" – Dr. Gunturu

**S2205**, "STOP CIPN: Randomized trial of Limb Cryocompression versus  
 ConTInuous cOmPression versus Low Cyclic Compression for the  
 Prevention of Taxane-InduCed perIPheral Neuropathy." Dr. Accordino

**S2010**, "Improving Endocrine Therapy Persistence in Young Women with  
 Breast Cancer using Active Symptom Monitoring." Dr. Henry

### Other Concepts in Development

Acupuncture to decrease symptom burden in patients with metastatic  
 breast cancer. Dr. Greenlee

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational,  
 cognitive rehabilitation program to improve perceived cognitive  
 function for cancer survivors. Dr. Myers

### Closed Trials

**S1614**, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in  
 Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving  
 Anti-Cancer Therapy for Solid Tumors." Dr. Hwang, Activated 2/21/19,  
 reactivated 7/1/21, Closed 11/15/2022

**S1714**, "A Prospective Observational Cohort Study To Develop A Predictive  
 Model Of Taxane-Induced Peripheral Neuropathy In Cancer Patients"- Dr.  
 Trivedi, Activated 3/1/19. Closed 11/15/2021

**S0702**, "A Prospective Observational Multicenter Cohort Study to Assess  
 the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with  
 Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak,  
 Activated 12/15/2008. Closed 12/13/2013.

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of  
 Acupuncture for Joint Symptoms Related to Aromatase Inhibitors  
 in Women with Early Stage Breast Cancer." Dr. Hershman. Activated:  
 3/27/2012. Closed: 2/15/2017

### Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What other updates should we know about
  - Patient Advocate update
  - Statistical Center update

### Other SWOG Studies with Symptom Control and QOL Component

#### Breast

**S1706**, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of  
 Olaparib Administered Concurrently with Radiotherapy for Inflammatory  
 Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

#### Cancer Care Delivery

**S1703**, "Randomized Non-Inferiority Trial Comparing Overall Survival  
 of Patients Monitored with Serum Tumor Marker Directed Disease  
 Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic  
 Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs.  
 Accordino, Hershman, and Ramsey. Activated: 7/16/18.

**S1912CD**, "A Randomized Trial Addressing Cancer-Related Financial  
 Hardship Through Delivery of a Proactive Financial Navigation  
 Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated:  
 7/26/21.

**S2108CD**, "A Cluster Randomized Trial Comparing an Educationally  
 Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice  
 to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter,  
 Trivedi, Symington, et al. Activated: 8/22/22.

# Symptom Control & Quality of Life Committee

## GU

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

## Leukemia

**S1925**, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

## Lung

**S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

**S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

## Lymphoma

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

## Myeloma

**S1803**, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

## Prevention and Epidemiology

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

## NCTN Studies

**CTSU/NRG-GI004**, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

## Symptom Control &amp; Quality of Life Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221702	A221805	A222004	EAQ202	EAZ171	NRGCC010
Ascension Providence Hospitals - Southfield	-	-	-	23	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	7	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	1	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	1	-	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	1	2	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-	-	-	-
Cancer Res of Wisconsin and N Michigan Consortium	-	-	-	67	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	8	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	22	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	27	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	3	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	10	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	12	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	54	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	4	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	1	20	-	-	-	-	-	1	3
Heartland Cancer Research NCORP	-	-	6	163	-	-	-	-	-	-	-
Henry Ford Hospital	8	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	2	4	38	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	1	46	-	-	-	-	-	-	-
MAVERIC	-	-	-	31	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved	-	-	-	-	-	-	-	-	-	2	-
Mercy Medical Center - Des Moines	-	-	-	9	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	2	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	39	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	4	-	-
Oregon Health and Science University	-	-	-	12	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	2	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	1	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	19	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	89	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	5	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	73	-	-	7	-	-	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	5	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	18	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	15	-	1	2	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	49	-	1	41	-	-	2	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	6	-	-	-	-	-	-	-	-
University of Rochester LAPS	15	-	-	-	-	14	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	29	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	1	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	2	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	17	-	-	-	-	-	-	-
ALLIANCE	5	-	2	189	2	-	-	-	-	-	-
ECOG-ACRIN	4	-	-	72	-	-	-	-	-	-	-
NRG	2	1	3	132	-	-	-	-	-	-	-
<b>Total</b>	<b>185</b>	<b>4</b>	<b>29</b>	<b>1,187</b>	<b>3</b>	<b>17</b>	<b>8</b>	<b>2</b>	<b>43</b>	<b>3</b>	<b>3</b>